Impact of the Xpert MTB/RIF diagnostic test for tuberculosis in countries with a high burden of disease

Current Opinion in Pulmonary Medicine

Volumn 21, Issue 3, 2015, Pages 304-308

  McNerney, Ruth ^a   Zumla, Alimuddin ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Diagnosis; Multidrug resistant tuberculosis; Point of care; tuberculosis

Indexed keywords

RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; HEALTH CARE COST; HUMAN; INFECTION CONTROL; LUNG TUBERCULOSIS; MICROSCOPY; MOLECULAR DIAGNOSIS; MORBIDITY; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; NUCLEIC ACID AMPLIFICATION; PATIENT IDENTIFICATION; POINT OF CARE TESTING; POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION SYSTEM; REVIEW; SPUTUM SMEAR; TIME TO TREATMENT; XPERT MTB RIF ASSAY; COST OF ILLNESS; ENDEMIC DISEASE; PROCEDURES; TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

ANTIBIOTICS, ANTITUBERCULAR; CLINICAL TRIALS AS TOPIC; COST OF ILLNESS; ENDEMIC DISEASES; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RIFAMPIN; TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 84926387005     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000161     Document Type: Review

References (23)

1. World Health Organisation. Global Tuberculosis Report. Geneva: WHO; 2014. WHO (Series Editor).
2. McNerney R, Daley P. Towards a point-of-care test for active tuberculosis: obstacles and opportunities. Nat Rev Microbiol 2011; 9:204-213.
3. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363:1005-1015.
4. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377:1495-1505.
5. Lawn SD, Mwaba P, Bates M, et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis 2013; 13:349-361.
6. Steingart KR, Sohn H, Schiller I, et al. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2013; 1:CD009593.
7. Lawn SD, Nicol MP. Xpert1 MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol 2011; 6:1067-1082.
8. Van Deun A, Maug AK, Bola V, et al. Rifampicin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 2013; 51:2633-2640.
9. DOTS Strategy Coordination Directorate. National Tuberculosis Control Guidelines. Pretoria: Department of Health, Republic of South Africa; 2014.
10. US Food and Drug Administration. Xpert MTB/RIF Assay 510(k) Decision Summary. USA; 2013.
11. World Health Organisation. Rapid Implementation of the Xpert MTB/RIF Diagnostic Test. Geneva: WHO; 2011. WHO (Series Editor).
12. Cox HS, Mbhele S, Mohess N, et al. ImpactofXpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial. PLoS Med 2014; 11:e1001760.
13. Durovni B, Saraceni V, van den Hof S, et al. Impact of replacing smear microscopy with Xpert MTB/RIF for diagnosing tuberculosis in Brazil: a stepped-wedge cluster-randomized trial. PLoS Med 2014; 11:e1001766.
14. Mupfumi L, Makamure B, Chirehwa M, et al. Impact of Xpert MTB/RIF on antiretroviral therapy-associated tuberculosis and mortality: a pragmatic ran domized controlled trial. Open Forum Infect Dis 2014; 1:ofu038.
15. Theron G, Zijenah L, Chanda D, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care set tings in Africa: a multicentre, randomised, controlled trial. Lancet 2014; 383:424-435.
16. Wejse C, Gustafson P, Nielsen J, et al. TBscore: signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course. Scand J Infect Dis 2008; 40:111-120.
17. Rudolf F, Joaquim LC, Vieira C, et al. The Bandim tuberculosis score: reliability and comparison with the Karnofsky performance score. Scand J Infect Dis 2013; 45:256-264.
18. Theron G, Peter J, Dowdy D, et al. Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings? Lancet Infect Dis 2014; 14:527-532.
19. Vanleeuw L. GeneXpert: an imperfect rollout. In: NSP Review. South Africa: Treatment Action Campaign; 2013.
20. Menzies NA, Cohen T, Lin HH, et al. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med 2012; 9:e1001347.
21. Dowdy DW, Houben R, Cohen T, et al. Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling. Int J Tuberc Lung Dis 2014; 18:1012-1018.
22. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med 2011; 8:e1001120.
23. Abdurrahman ST, Emenyonu N, Obasanya OJ, et al. The hidden costs of installing Xpert machines in a tuberculosis high-burden country: experiences from Nigeria. Pan Afr Med J 2014; 18:277.